Marshall Wace LLP Trims Stake in Personalis, Inc. (NASDAQ:PSNL)

Marshall Wace LLP lessened its position in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 84.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,010 shares of the company's stock after selling 386,966 shares during the period. Marshall Wace LLP owned about 0.10% of Personalis worth $405,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in PSNL. Barclays PLC raised its position in Personalis by 45.4% in the third quarter. Barclays PLC now owns 65,468 shares of the company's stock valued at $352,000 after purchasing an additional 20,444 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Personalis by 20.0% during the third quarter. Geode Capital Management LLC now owns 498,470 shares of the company's stock worth $2,683,000 after purchasing an additional 83,068 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Personalis in the fourth quarter worth $63,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Personalis during the 4th quarter valued at $87,000. Finally, abrdn plc purchased a new stake in shares of Personalis during the 4th quarter valued at approximately $1,722,000. Institutional investors own 61.91% of the company's stock.

Personalis Price Performance

NASDAQ:PSNL traded down $0.15 during trading hours on Friday, hitting $5.01. The company had a trading volume of 341,897 shares, compared to its average volume of 996,043. Personalis, Inc. has a 52 week low of $1.14 and a 52 week high of $7.20. The company has a market capitalization of $442.42 million, a PE ratio of -2.98 and a beta of 1.83. The stock has a 50-day moving average price of $3.65 and a 200 day moving average price of $4.46.

Personalis (NASDAQ:PSNL - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The company had revenue of $20.61 million during the quarter, compared to the consensus estimate of $17.41 million. Analysts anticipate that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on PSNL. HC Wainwright upped their target price on Personalis from $8.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday. Needham & Company LLC reissued a "buy" rating and set a $7.00 price objective on shares of Personalis in a report on Thursday, April 10th. Finally, Craig Hallum began coverage on shares of Personalis in a research report on Monday, March 17th. They issued a "buy" rating and a $8.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $8.00.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.